Role of the EPA: DHA dosing ratio in omega-3 supplements on blood fatty acid profiles and inflammation: a systematic review and meta-analysis
Khabir Z, Abdelhafez A, Camponovo F, Joyce P, Garcia-Bennett A
Critical reviews in food science and nutrition · 1 cita
Cómo se estudió
- Diseño
- Metaanálisis (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación independiente
- Gobierno
- Australian Research Council Industrial Transformation Training Centre for Facilitated Advancement of Australia’s Bioactives
Según 1 financiador declarado.
Publicación
- Publicado
- 2026-01-22 · Crit Rev Food Sci Nutr · vol. 66 · número 20 · págs. 3866–3887
- Editorial
- Taylor & Francis
- Citado
- 5 citas · más que el 99% de estudios similares · 14.1× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 162 trabajos
- Acceso
- De pago
- Áreas de investigación
- Fatty Acid Research and Health · Eicosanoids and Hypertension Pharmacology · Vitamin K Research Studies
- Palabras clave
- Dosing, Docosahexaenoic acid, Eicosapentaenoic acid, Bioavailability, Pharmacokinetics, Whole blood, Arachidonic acid, Fatty acid
- MeSH
- humans, inflammation, docosahexaenoic acids, eicosapentaenoic acid, fatty acids, arachidonic acid, tumor necrosis factor-alpha, c-reactive protein, anti-inflammatory agents, interleukin-6, dietary supplements, biomarkers
5 autores
- Zahra Khabir🇦🇺 · autor de correspondenciaAustralian Research Council; Macquarie University
- Amer Abdelhafez🇦🇺Australian Research Council; University of South Australia
- Fabrizio F. Camponovo🇦🇺Australian Research Council
- Paul Joyce🇦🇺Australian Research Council; University of South Australia
- Alfonso Garcia-Bennett🇦🇺Australian Research Council; Macquarie University
Resumen
El texto original del estudio, en el idioma en que se publicó.
Most omega-3 supplements contain eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in defined ratios, yet their pharmacokinetic and anti-inflammatory effects are not fully understood. This systematic review and meta-analysis evaluated how EPA:DHA dosing ratios, alongside EPA+DHA daily dose, influence blood fatty acid profiles and inflammatory markers across 96 clinical trials published before February 2025. Standardized mean differences with 95% confidence intervals were calculated. EPA+DHA supplementation significantly increased EPA:DHA blood ratios and blood EPA+DHA levels, with larger effects in healthy individuals. Supplementation also reduced arachidonic acid (AA) and key inflammatory markers, C-reactive protein (CRP), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6), particularly in participants with underlying health conditions. Ratios <1.0 produced the greatest cytokine reductions, whereas ratios ≥1.0 most effectively increased the EPA:DHA blood ratio and lowered AA. EPA+DHA doses of 1-3 g/day were associated with the most consistent reductions in CRP, TNF-α, and IL-6. Linear regression showed a strong association between the EPA:DHA dosing ratio and the EPA:DHA blood ratio and identified the EPA:DHA blood ratio as the strongest predictor of AA reduction. These findings indicate distinct ratio- and dose-dependent effects of EPA and DHA and highlight the importance of optimizing omega-3 formulations to enhance bioavailability and anti-inflammatory outcomes.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.